Skip to search formSkip to main contentSkip to account menu

xanomeline

Known as: (3-O-hexyloxy)-TZTP, 3-(3-O-hexyl-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

LY 246708xanomeline tartrate

Broader (5)

Muscarinic AgonistsParasympathomimetic AgentsPsychotropic DrugsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Classics in Chemical Neuroscience: Xanomeline.
Xanomeline (1) is an orthosteric muscarinic acetylcholine receptor (mAChR) agonist, often referred to as M1/M4-preferring, that… 
Review
2014
Review
2014
Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia
Alzheimer’s disease (AD) and schizophrenia (SZ) are neurological disorders with overlapping symptomatology, including both… 
Review
2013
Review
2013
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Highly Cited
2010
Highly Cited
2010
Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One?
“Intrinsic” and “idiosyncratic” drug-induced liver injury reactions are commonly thought to arise by different modes of action… 
Review
2006
Review
2006
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M(1) receptor… 
Highly Cited
2005
Highly Cited
2005
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite…
RationaleRecent studies have suggested that the salutary actions of clozapine in schizophrenia may be due to selective activation… 
Review
2004
Review
2004
Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists
RationaleAlterations in the central cholinergic system of patients with schizophrenia such as reduced numbers of muscarinic and… 
Highly Cited
2001
Highly Cited
2001
The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
The muscarinic receptor agonist xanomeline was examined and compared with the antipsychotics clozapine and/or haloperidol in the… 
Highly Cited
1999
Highly Cited
1999
The assessment of antagonist potency under conditions of transient response kinetics.
Highly Cited
1997
Highly Cited
1997
Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
OBJECTIVE Higher than normal cellular levels of the phospholipid catabolic intermediate glycerophosphocholine have been found in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)